Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma
Suzanne D. Turner(MRC Laboratory of Molecular Biology), Marshall E. Kadin(Roger Williams Medical Center)
Cited by 54
Related Papers
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
|Cancers|2018|86
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
|Nature Communications|2019|42
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
|Nature Communications|2024|14
CD30 Regulation of IL-13–STAT6 Pathway in Breast Implant–Associated Anaplastic Large Cell Lymphoma
|Aesthetic Surgery Journal|2022|7
IL-13 Signaling in CD30+ Cutaneous Lymphoproliferative Disorders
|Journal of Investigative Dermatology|2020|5